YZYanxia Zhang

Yanxia Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanxia Zhang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Xiao

    Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University

    2 shared publications
  • Keping Xie

    Center for Pancreatic Cancer Research, The South China University of Technology School of Medicine, Guangzhou, Guangdong 510006, China

    2 shared publications
  • Linhai Li

    Guangzhou Medical University

    2 shared publications
  • Yunduo Liu

    Department of Laboratory Medicine, The Sixth School of Clinical Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China

    2 shared publications
  • Changqing Chang

    Integrative Microbiology Research Center, Engineering Research Center of Biological Control, Ministry of Education, College of Plant Protection, South China Agricultural University, Guangzhou, 510642, China

    1 shared publication
  • Chengrui Wang

    Division of Birth Cohort Study, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University , Guangzhou 510623

    1 shared publication

Latest Publications

  • Open Access

    Clinical Relevance and Drug Modulation of PPAR Signaling Pathway in Triple‐Negative Breast Cancer: A Comprehensive Analysis

    by Yanxia Zhang, Yunduo Liu, Mei Zhang, Guanjie Li, Siling Zhu, Keping Xie, Bin Xiao, Linhai Li

    Triple‐negative breast cancer (TNBC) is highly heterogeneous and poses a significant medical challenge due to limited treatment options and poor outcomes. Peroxisome proliferator‐activated receptors (PPARs) play a crucial role in regulating metabolism and cell fate. While the association between PPAR signal and human cancers has been a topic of concern, its specific relationship with TNBC remains unclear. Integrated analysis of large published datasets from clinical cohorts and cell lines through databases has proven to be a powerful and essential approach for understanding cancer and uncovering new molecular targets. Here, we conducted a comprehensive study investigating the clinical relevance and drug modulation of the PPAR signaling pathway in TNBC, using data from The Cancer Genome Atlas (TCGA) for TNBC patients and Genomics of Drug Sensitivity in Cancer (GDSC) for TNBC cell lines, along with drug perturbation information from Connectivity Map (CMap). In the TCGA‐TNBC cohort, higher PPAR signaling activity was not associated with clinical stage, prognosis, tumor mutational burden, microsatellite instability, homologous recombination deficiency, stemness, or proliferation status. However, it was linked to older age; an elevated rate of piccolo presynaptic cytomatrix protein (PCLO) mutations; and oncogenic signal transduction involving MAPK, Ras, and PI3K‐Akt pathways. Additionally, it influenced biological pathways including fatty acid metabolism, AMPK signaling, and ferroptosis. Strikingly, higher PPAR activity appeared to promote the formation of an antitumor immune and microbial microenvironment. In the GDSC‐TNBC cells, nevertheless, it seemed to incur chemoresistance. Furthermore, we identified a batch of potential compounds that can regulate the PPAR signaling pathway. Lastly, our experimental validation demonstrated the ability of the histone deacetylase (HDAC) inhibitor chidamide to activate the PPAR signal in TNBC cells. In conclusion, the PPAR signaling pathway likely has pleiotropic biological effects in TNBC. These preliminary but interesting findings enhance our understanding of the role played by PPAR signal and provide new insights into the heterogeneity driven by it in TNBC.


  • Roles of PPAR activation in cancer therapeutic resistance: Implications for combination therapy and drug development

    by Yanxia Zhang, Bin Xiao, Yunduo Liu, Shunhong Wu, Qin Xiang, Yuhan Xiao, Junxiu Zhao, Ruanfei Yuan, Keping Xie, Linhai Li


  • Open Access

    SARS-Cov-2-, HIV-1-, Ebola-neutralizing and anti-PD1 clones are predisposed

    by Yanfang Zhang, Qingxian Xu, Huikun Zeng, Minhui Wang, Yanxia Zhang, Chunhong Lan, Xiujia Yang, Yan Zhu, Yuan Chen, Qilong Wang, et al.

    Antibody repertoire refers to the totality of the superbly diversified antibodies within an individual to cope with the vast array of possible pathogens. Despite this extreme diversity, antibodies of the same clonotype, namely public clones, have been discovered among individuals. Although some public clones could be explained by antibody convergence, public clones in naïve repertoire or virus-neutralizing clones from not infected people were also discovered. All these findings indicated that public clones might not occur by random and they might exert essential functions. However, the frequencies and functions of public clones in a population have never been studied. Here, we integrated 2,449 Rep-seq datasets from 767 donors and discovered 5.07 million public clones – ~10% of the repertoire are public in population. We found 38 therapeutic clones out of 3,390 annotated public clones including anti-PD1 clones in healthy people. Moreover, we also revealed clones neutralizing SARS-CoV-2, Ebola, and HIV-1 viruses in healthy individuals. Our result demonstrated that these clones are predisposed in the human antibody repertoire and may exert critical functions during particular immunological stimuli and consequently benefit the donors. We also implemented RAPID – a R ep-seq A nalysis P latform with I ntegrated D atabases, which may serve as a useful tool for others in the field.